Market Size of France Insulin Infusion Pump Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 130.74 Million |
| Market Size (2029) | USD 159.56 Million |
| CAGR (2024 - 2029) | 4.06 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
France Insulin Infusion Pump Market Analysis
The France Insulin Infusion Pump Market size is estimated at USD 130.74 million in 2024, and is expected to reach USD 159.56 million by 2029, growing at a CAGR of 4.06% during the forecast period (2024-2029).
Diabetes was one of the most prominent risk factors for a severe COVID-19 course. This risk was assumed to be influenced by several diabetes-related variables. Factors include age, a proinflammatory and hypercoagulable condition, hyperglycemia, hypertension, cardiovascular disease, chronic renal disease, and obesity. Diabetes was recognized as a risk factor for poor outcomes early in the COVID-19 pandemic. As a result, managing or delaying the onset of type-2 diabetes was more important than ever. During the COVID-19 pandemic, diabetic medicines were evaluated as potential therapies for people with diabetes infected with SARS-CoV-2.
Diabetes drugs are medications used to control and stabilize blood glucose levels in people with diabetes. Diabetes drugs are frequently used to treat the condition. Diabetes drugs are divided into various groups. Each type of medication has a distinct mechanism of action for decreasing blood sugar. A drug may work by stimulating the pancreas to make and release more insulin, decreasing the liver's ability to generate and release sugar, suppressing the activity of enzymes in the intestines that break down carbohydrates, and various other ways. It also increases insulin sensitivity in cells, lowering the kidneys' ability to absorb sugar and increasing the amount of sugar excreted in the urine.
Diabetes has the highest prevalence of any chronic disease covered by France's statutory health insurance (SHI), and the number of insured patients has more than doubled in the previous decade. Diabetes is growing increasingly widespread among individuals of all ages in France, which can be attributed to increased obesity, poor diets, and sedentary lives. Thus, growing diabetes and obesity prevalence, higher diabetic care awareness, increased healthcare spending, and technological advancements drive the French pump market.
France Insulin Infusion Pump Industry Segmentation
An insulin pump delivers insulin to control blood sugar and minimize hypoglycemia's effects. The pump comprises a pump reservoir like an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes. France's insulin infusion pumps market is segmented by component (pump device, infusion set, and reservoir). The report offers the value (USD) and Volume (units) for the above segments.
| Insulin Infusion Pump | |
| Insulin Pump Device | |
| Infusion Set | |
| Reservoir |
France Insulin Infusion Pump Market Size Summary
The France insulin infusion pump market is poised for growth, driven by the increasing prevalence of diabetes and obesity, heightened awareness of diabetic care, and advancements in healthcare technology. Insulin pumps, which offer a continuous or on-demand insulin delivery system, are becoming a preferred alternative to traditional injection methods, particularly for individuals with type 1 diabetes. These devices mimic the pancreas's natural insulin release, providing better glycemic control. Despite the promising growth trajectory, the market faces challenges, including the need for more diabetes educators and the promotion of insulin pump therapy over multi-injection treatments. The French healthcare system supports diabetes management through free access to insulin and related supplies, although there is a need for more ambitious policies to promote healthy eating habits.
The competitive landscape of the French insulin infusion pump market is concentrated, with a few major players like Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care dominating the scene. Recent strategic moves, such as Medtronic's acquisition of EOFlow Co. Ltd. and Novo Nordisk's negotiations with BIOCORP, highlight the industry's focus on expanding product offerings and enhancing technological capabilities. These developments, coupled with increased public awareness and international research collaborations, are expected to drive market growth. The market's expansion is further supported by the availability of innovative diabetes medications and the integration of e-health solutions, although the utilization of existing health data registries remains limited.
France Insulin Infusion Pump Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulin Infusion Pump
-
2.1.1 Insulin Pump Device
-
2.1.2 Infusion Set
-
2.1.3 Reservoir
-
-
France Insulin Infusion Pump Market Size FAQs
How big is the France Insulin Infusion Pump Market?
The France Insulin Infusion Pump Market size is expected to reach USD 130.74 million in 2024 and grow at a CAGR of 4.06% to reach USD 159.56 million by 2029.
What is the current France Insulin Infusion Pump Market size?
In 2024, the France Insulin Infusion Pump Market size is expected to reach USD 130.74 million.
